Method for treating hyperkalemia with poly(2-fluoroacrylic acid-pentaerythritol triallyl ether) iron calcium sodium salt
By using poly(2-fluoroacrylate-pentaerythritol triallyl ether) iron calcium sodium salt to treat hyperkalemia, the problems of slow onset of action, multiple side effects, and poor patient compliance of existing drugs have been solved. This method achieves rapid reduction of blood potassium levels and avoids adverse reactions, thus improving the safety of treatment and patient compliance.
Patent Information
- Application Number
- PCT/CN2025/119237
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-13
- Filing Date
- 2025-09-05
- Publication Date
- 2026-03-19
AI Technical Summary
Existing medications for hyperkalemia have problems such as slow onset of action, numerous side effects, adverse reactions to sodium ion exchange-induced edema, adverse reactions to magnesium ...
Poly(2-fluoroacrylate-pentaerythritol triallyl ether) iron calcium sodium salt was used as the cation exchange resin to address adverse reactions such as edema, magnesium ion exchange-induced edema, magnesium ion exchange-induced edema, magnesium ion exchange-induced edema, hypomagnesemia, and poor patient compliance.
It achieves rapid reduction of serum potassium levels, avoids adverse reactions such as edema and hypomagnesemia, improves patient compliance, and has a rapid onset of action, effectively reducing serum potassium levels within 1 hour after the first dose.